细胞因子释放综合征
医学
嵌合抗原受体
中性粒细胞减少症
淋巴瘤
肿瘤科
内科学
临床试验
免疫学
毒性
免疫疗法
癌症
作者
Samuel Yamshon,Caitlin Gribbin,Mohammad Alhomoud,Nora Chokr,Zhengming Chen,Michelle Demetres,Michelle Pasciolla,John P. Leonard,Tsiporah B. Shore,Peter Martin
标识
DOI:10.1016/j.clml.2024.02.007
摘要
The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate.
科研通智能强力驱动
Strongly Powered by AbleSci AI